The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith ...

A simple blood draw has now become a powerful tool in the early fight against Alzheimer’s. The FDA has approved the first ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing ...

Dr. Richard G. Stefanacci explains why the FDA's recent clearance of a diagnostic blood test for Alzheimer's deserves ...

The test allows for much earlier detection of the disease, even before clear memory or behavioural symptoms appear ...

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the brain, a hallmark of Alzheimer’s disease.

Last week, the US Food & Drug Administration approved marketing for a blood test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, developed by the Pennsylvania-based biotechnology company ...

Cleared for marketing on Wednesday, the Lumipulse G pTau217/ß-Amyloid 1-42 plasma ratio test identifies amyloid plaques, one of the key hallmarks of Alzheimer’s, in adults aged 55 and older who ...

The FDA has cleared the first blood test to diagnose Alzheimer's which works by measuring the amount of pTau 217 and beta-amyloid 1-42 in plasma.